Trials / Completed
CompletedNCT00744224
PREDnisolone-induced Beta-cell Dysfunction Prevented by EXenatide
Prednisolone-induced Impairment of Glucose Metabolism and Beta-cell Dysfunction and the Protective Effects of Exenatide: a Single-center, Randomized, Double-blind, Placebo-controlled Crossover Study in Healthy Volunteers
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 8 (estimated)
- Sponsor
- Amsterdam UMC, location VUmc · Academic / Other
- Sex
- Male
- Age
- 18 Years – 35 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to explore whether the GLP-1 receptor agonist exenatide, may prevent glucocorticoid-induced glucometabolic abnormalities and beta-cell dysfunction in healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Single dose of placebo with saline infusion |
| DRUG | Prednisolone | Single dose of 80 mg prednisolone with saline infusion |
| DRUG | Prednisolone and Exenatide | Prednisolone 80 mg single dose Exenatide infusion 20 mg/min |
Timeline
- Start date
- 2009-02-01
- Primary completion
- 2010-01-01
- Completion
- 2010-01-01
- First posted
- 2008-08-29
- Last updated
- 2010-01-13
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT00744224. Inclusion in this directory is not an endorsement.